Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Invested Capital (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Invested Capital for 13 consecutive years, with $942.6 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 8.1% to $942.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $942.6 million through Dec 2025, up 8.1% year-over-year, with the annual reading at $942.6 million for FY2025, 8.1% up from the prior year.
  • Invested Capital for Q4 2025 was $942.6 million at Madrigal Pharmaceuticals, down from $965.5 million in the prior quarter.
  • The five-year high for Invested Capital was $973.7 million in Q2 2024, with the low at $78.5 million in Q3 2022.
  • Average Invested Capital over 5 years is $502.6 million, with a median of $268.9 million recorded in 2021.
  • The sharpest move saw Invested Capital plummeted 66.57% in 2022, then soared 422.52% in 2024.
  • Over 5 years, Invested Capital stood at $196.1 million in 2021, then soared by 36.18% to $267.1 million in 2022, then soared by 95.01% to $520.8 million in 2023, then surged by 67.42% to $872.0 million in 2024, then rose by 8.1% to $942.6 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $942.6 million, $965.5 million, and $814.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.